BostonGene vs Caris Life Sciences (2026)
Both profile a tumour and they model different things about it. Caris runs comprehensive molecular profiling with an approved assay doing simultaneous whole exome and whole transcriptome sequencing, published validation and signatures that disclose their training cohorts, delivered into a molecular tumour board. BostonGene models tumour and immune biology together, integrating data types into a portrait of the microenvironment rather than a variant report, and applies the same models to clinical care and to drug development. The clinical question decides it. If you need the actionable alterations and a defensible regulatory footing for the assay, Caris. If the question is immune context, why a therapy is not working or who might respond, BostonGene is modelling the thing you are asking about. Neither publishes performance by ancestry, which is the shared blind spot of this entire category.
- The tumour and immune biology modelling is the product rather than the sequencing, integrating multiple data types into a portrait that describes the microenvironment rather than a variant list.
- It serves both clinical care and drug development from the same models, which means the platform is exercised against research grade questions as well as clinical ones.
- For a programme whose question is why a patient is not responding rather than which mutation is present, immune context is where the answer usually sits.
- The approved assay is a regulatory distinction the company documents rather than blurs, and simultaneous whole exome and whole transcriptome sequencing under that approval is a genuinely different footing from laboratory developed testing.
- Clinical and analytical validation is published and the artificial intelligence signatures disclose their training cohorts and sizes.
- Scope is precisely bounded to solid tumour profiling across adult and paediatric patients, which is a clearer intended use statement than most competitors publish.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BostonGene and Caris Life Sciences are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BostonGene | Caris Life Sciences |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Headquarters | Waltham, Massachusetts | Irving, Texas |
| Website | bostongene.com | carislifesciences.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BostonGene its top capability grade on Clinical and Operational Evidence and Setting and Specialty Coverage. Set against Caris Life Sciences, BostonGene grades higher on Model and Technology Transparency and AI Governance and Bias Disclosure. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Caris Life Sciences its top capability grade on several axes, including Clinical and Operational Evidence, HIPAA and BAA Posture and FDA and Regulatory Status. Set against BostonGene, Caris Life Sciences grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose BostonGene or Caris Life Sciences?
On the axes where the AI Health Index separates them, BostonGene grades higher on Model and Technology Transparency and AI Governance and Bias Disclosure, and Caris Life Sciences grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Caris Life Sciences leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do BostonGene and Caris Life Sciences differ most?
The widest separation the AI Health Index records between BostonGene and Caris Life Sciences is on Model and Technology Transparency, where BostonGene grades B and Caris Life Sciences grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do BostonGene and Caris Life Sciences grade the same?
The AI Health Index grades BostonGene and Caris Life Sciences the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BostonGene and Caris Life Sciences not disclosed?
At the last review, at least one of BostonGene and Caris Life Sciences published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Neither vendor publishes a governance framework, subgroup performance analysis or bias evaluation, and in precision oncology the omission is specific: signature and interpretation performance depend on the ancestral and demographic composition of the training cohorts, and a signature validated mainly in one population will perform differently in another without any signal that it has. Neither publishes a security attestation or trust centre.
Both operate their own laboratories and report their own performance, so the evidence is internally generated even where it is published, and independent replication is largely absent from this category.